MET and head and neck squamous cell carcinoma: AXL and MET have been suggested to increase resistance of MAPKi and have shown synergies with MAPKi in non-HNSCC models.27 However, despite the observation of synergy between AXL/MET inhibition and trametinib combination treatment, there seemed to be a reduction in the overall AXL and MET expression in trametinib-treated cells, suggesting that the cells that are sensitive to trametinib may be the same cells that highly express AXL and MET (Supplementary Fig. S8).